Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381693 | 0.91 | FOLH1 (0.51) | FOLH1HSD17B10MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL23705394 | 0.90 | PKM (0.45) | FOLH1HSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL4275480 | 0.85 | FOLH1 (0.67) | FOLH1HSD17B10MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL26427320 | 0.84 | FOLH1 (0.47) | FOLH1HSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL23710366 | 0.84 | FOLH1 (0.47) | FOLH1HSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL23710384 | 0.84 | FOLH1 (0.47) | FOLH1HSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL7051409 | 0.84 | FOLH1 (0.52) | FOLH1HSD17B10MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL17504759 | 0.84 | HSD17B10 (0.53) | FOLH1HSD17B10MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL20214855 | 0.84 | MEN1 (0.45) | FOLH1ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL14102848 | 0.84 | FOLH1 (0.51) | FOLH1HSD17B10MAPK1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-13 | — | — | US | disclosed |
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885HSD17B10 1728/4885MAPK1 2765/4885 |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885HSD17B10 1946/4885MAPK1 3145/4885 |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885HSD17B10 1728/4885MAPK1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.